Delaware Court Gives Go Ahead on More Than 70,000 Zantac Trials 

More than 70,000 Zantac cases may go to trial following Delaware Superior Court Judge Vivian Medinilla’s order allowing plaintiffs’ expert witnesses to testify in court that the drug may cause cancer.

Defendants Boehringer Ingelheim, GSK, Pfizer and Sanofi challenged ten expert witnesses and Emery Pharma, a contract research laboratory.

Judge Medinilla explained that the court was ruling on the parties’ competing motions to exclude expert testimony under Rule 702 of the Delaware Rules of Evidence. In her decision, she said that “It would be improper to simply dismiss these experts as ‘poseurs or witnesses for hire. They are serious scientists,’” adding that “Any remaining challenges will be made at trial via cross-examination and introduction of counter evidence.

To read the whole story, click here.

Related Topics